复星医药(600196.SH)：控股子公司药品顺铂注射液注册申请获受理

Core Viewpoint - Fosun Pharma's subsidiary, Jisimei (Wuhan) Pharmaceutical Co., Ltd., has had its drug registration application for Cisplatin Injection accepted by the National Medical Products Administration, indicating progress in the development of this self-developed chemical drug for treating metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer [1]. Group 1 - The drug in question, Cisplatin Injection, is developed by the company and is intended for the treatment of specific types of cancer [1]. - The acceptance of the drug registration application marks a significant milestone for the company in expanding its oncology product portfolio [1].